You are here

Spinraza

US/EU regulators start review of Biogen's high-dose Spinraza

Pharmaphorum

Thu, 01/23/25 - 11:39 am

5 Reasons Biogen’s Shares Have Dropped 36% in 2024

BioSpace

Thu, 11/14/24 - 11:19 am

Biogen fills in some of the blanks on its trial of a high-dose version of Spinraza

Fierce Pharma

Wed, 10/9/24 - 09:52 am

spinal muscular atrophy

Biogen to seek approval for high-dose version of SMA stalwart Spinraza after trial win

Fierce Pharma

Wed, 09/4/24 - 10:49 pm

spinal muscular atrophy

Spinal Muscular Atrophy: Four trials to watch over the next 12 months

Clinical Trials Arena

Fri, 08/11/23 - 11:39 am

clinical trials

spinal muscular atrophy

Biogen, scrapping for SMA market share, bets $10M on implant to improve delivery of Spinraza

Fierce Pharma

Tue, 01/10/23 - 10:55 am

Alcyone Therapeutics

Biogen Announces New Spinraza Data Ahead of Presentation

BioSpace

Mon, 03/14/22 - 11:39 pm

spinal muscular atrophy

Biogen brings in a successor to Spinraza

BioPharma Dive

Tue, 01/4/22 - 10:49 pm

Ionis Pharmaceuticals

spinal muscular atrophy

Citing 'less-than-optimal' outcomes for Roche's Evrysdi, Biogen launches high-dose Spinraza trial

Fierce Pharma

Thu, 09/16/21 - 10:52 am

spinal muscular atrophy

Zolgensma flatlines, but Spinraza isn’t the beneficiary

EP Vantage

Wed, 04/28/21 - 10:27 am

Biogen Reports New Spinraza Data in SMA

Global Genes

Wed, 04/21/21 - 10:34 am

2 Fumbles and 1 Gift in Biogen's Latest Earnings Report

Motley Fool

Wed, 10/28/20 - 10:38 am

Biogen is running out of safety nets

BioPharma Dive

Thu, 10/22/20 - 10:53 am

From no drugs to 3: Patients with spinal muscular atrophy now face hard choices

BioPharma Dive

Mon, 10/5/20 - 11:39 pm

spinal muscular atrophy

Biogen to Run Phase IV SMA Trial: “I Want to Optimize Their Life.”

BioSpace

Wed, 08/12/20 - 12:14 am

spinal muscular atrophy

clinical trials

Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients

MedCity News

Tue, 07/21/20 - 10:37 am

clinical trials

spinal muscular atrophy

Biogen’s Spinraza Shows Sustained Benefit for Pre-Symptomatic SMA Patients

BioSpace

Wed, 06/10/20 - 11:46 pm

clinical trials

Roche’s risdiplam delay a relief for SMA rivals Biogen and Novartis—for now: analyst

Fierce Pharma

Wed, 04/8/20 - 11:03 am

Should Biogen's Spinraza for SMA be delayed amid COVID-19? No, say these parents

Fierce Pharma

Fri, 03/27/20 - 12:02 am

Roche, PTC will now get an FDA decision on their SMA drug in 6 months — facing off with Biogen, Novartis

Endpoints

Mon, 11/25/19 - 09:52 am

PTC Therapeutics

Pages